about
A proposed classification of the immunological diseasesHearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonismNALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorderHeterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypesMutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune responseGenetics of type 1 diabetes mellitusHereditary auto-inflammatory disorders and biologicsPrimer: inflammasomes and interleukin 1beta in inflammatory disordersThe tumour necrosis factor receptor-associated periodic syndrome: current conceptsThe EIF2AK3 gene region and type I diabetes in subjects from South IndiaEffects of diltiazem on long-term outcome after acute myocardial infarction in patients with and without a history of systemic hypertension. The Multicenter Diltiazem Postinfarction Trial Research GroupPhospholipase D1b and D2a generate structurally identical phosphatidic acid species in mammalian cellsCompounded Bioidentical Hormones in Endocrinology Practice: An Endocrine Society Scientific Statement.Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO reviewHistorical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review.Salmonella sepsis caused by a platelet transfusion from a donor with a pet snake.Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a Dutch family: evidence for a TNFRSF1A mutation with reduced penetrance.A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease.The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guidelineThe role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guidelineThe role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics.The MHC big bang.Exclusion of the familial Mediterranean fever locus as a susceptibility region for autosomal dominant familial Hibernian fever.Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypesAutosomal dominant recurrent fevers. Clinical and genetic aspects.TNFRSF1A mutations and autoinflammatory syndromes.Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.Evolution of a stream ecosystem in recently deglaciated terrain.Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects.Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients.Clinical presentation of and outcome for solitary rectal ulcer syndrome in children.TNF and TNFR biology in health and disease.Linkage of familial Hibernian fever to chromosome 12p13.Hereditary periodic fever syndromes.Caudate Volume in Offspring at Ultra High Risk for Alcohol Dependence: COMT Val158Met, DRD2, Externalizing Disorders, and Working Memory.Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.Inflammasomes and autoimmunityUse of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up.Cytokine gene polymorphism in human disease: on-line databases, supplement 2.
P50
Q21144701-5CB137CB-2516-42D9-942D-451422BF1F3DQ24307718-624BED5B-2E78-48C5-A5A7-E141A5488F13Q24317771-92326122-C182-4679-97BE-4C19F1298633Q24329184-1CD81135-DD92-4F4D-B282-7E64F3296B3BQ24338296-8590929D-2529-4A36-85DC-B0065476BDD7Q28215982-4938C1C2-7FEF-4C34-8382-3BD753C93D9FQ28243289-88F5D976-24D6-4145-BD82-8F72B700B1A7Q28263370-95ADA6F6-51D1-41AA-95F1-048037852C7CQ28276478-A34EB79C-353E-4CB8-8416-1B6B6D3A68C6Q28287813-BA6764F1-5DE3-4BB1-AE12-A789682B957AQ28327564-641FF951-11CE-4C85-9AC9-CF6A53D28AA2Q28365884-C3AA6E24-F879-4507-9336-B3FCE9261195Q30277062-9D7C5833-C066-4221-9078-B52D4A2B90A5Q30356126-98E71820-9230-4756-87F7-E20A6F492A8DQ30393860-692D789B-65D2-4E3E-A59A-D3C2E426D276Q31113265-D5A5CE48-5044-47F5-8725-53E4DBC320DDQ31929118-0A3BE55B-65ED-4C82-99EE-0B531CE69D69Q32062079-45F0960D-E023-4A39-B546-29EEBF1A6382Q33599104-E0159A02-63D1-4035-BDA7-9E5076F5D89EQ33599111-6464F236-BFAA-498E-80E1-3E085751B300Q33599118-25FD5A87-F2E9-47ED-A2DA-B1D37C70037DQ33599167-7B7890D4-B483-4C0D-B850-77890D750417Q33630607-7CCCD7C0-BE55-4CAC-825F-1B772B3282BCQ33680761-9D4C26FD-FA99-45C0-8CF8-E07B9553215CQ33732183-18D225B4-A18F-4BCC-BDCC-E530846FB6DDQ33776768-0CC76D2F-AB94-44C3-9521-26BBA76A260CQ33971049-36A4D08A-D5C4-4F84-A632-C925C97C4376Q34025008-5BB92E86-EB42-45D5-BC57-489E78AB204DQ34072033-8D307616-CD93-47D2-8AC1-0E82D9A55059Q34128577-D93BA95F-EE4E-4B6C-8F9F-70C3302B227EQ34134975-29A79C30-8AEE-48DA-B6E6-6EB01D22CDDAQ34248817-524C69F6-675E-4AD4-A678-183EB524932CQ34335336-30576497-E298-4E10-8A68-DD01B985F7E2Q34385794-3B4E0863-6CE6-4C30-B958-03D4B1399AD4Q34389056-14EA99E8-F92E-4506-82EC-07C52D48B481Q34429452-43A830B7-E4DD-4C28-A2C3-A36557BD5619Q34649706-66C68C72-AA07-4445-98FC-2B09E76E0EB2Q34670542-9EAEF51F-C8C9-45CE-98A7-697BCBBAA5C3Q34747396-082B7612-0DEA-40CC-80B1-A5B2E4A6CD79Q34810493-3092D538-6350-4EA8-89CE-ECC3EF00BBC3
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
researcher
@en-ca
researcher
@en-gb
հետազոտող
@hy
name
Michael McDermott
@ast
Michael McDermott
@br
Michael McDermott
@ca
Michael McDermott
@cs
Michael McDermott
@cy
Michael McDermott
@da
Michael McDermott
@de
Michael McDermott
@de-at
Michael McDermott
@de-ch
Michael McDermott
@en
type
label
Michael McDermott
@ast
Michael McDermott
@br
Michael McDermott
@ca
Michael McDermott
@cs
Michael McDermott
@cy
Michael McDermott
@da
Michael McDermott
@de
Michael McDermott
@de-at
Michael McDermott
@de-ch
Michael McDermott
@en
altLabel
Michael F McDermott
@br
Michael F McDermott
@ca
Michael F McDermott
@cs
Michael F McDermott
@cy
Michael F McDermott
@da
Michael F McDermott
@de
Michael F McDermott
@de-at
Michael F McDermott
@de-ch
Michael F McDermott
@en
Michael F McDermott
@en-ca
prefLabel
Michael McDermott
@ast
Michael McDermott
@br
Michael McDermott
@ca
Michael McDermott
@cs
Michael McDermott
@cy
Michael McDermott
@da
Michael McDermott
@de
Michael McDermott
@de-at
Michael McDermott
@de-ch
Michael McDermott
@en
P106
P1153
55630653800
P21
P2798
P31
P496
0000-0002-1015-0745